绝经年龄与激素治疗使用与Tau蛋白及β淀粉样蛋白正电子发射断层扫描的关联
这项横断面研究纳入威斯康星阿尔茨海默病预防登记处292名认知正常者(女性193名,男性99名),发现雌性性别、较早绝经年龄和激素治疗使用在β淀粉样蛋白升高时与区域tau正电子发射断层扫描摄取较高相关,且激素治疗晚启动(绝经后超过5年)与tau较高相关。
要点
- 在β淀粉样蛋白升高个体中,女性较男性、较早绝经年龄较晚绝经年龄、激素治疗使用较未使用与区域tau正电子发射断层扫描摄取较高相关。
- 受累区域包括颞叶和枕叶的内侧和外侧区域。
- 激素治疗晚启动(绝经后超过5年)与较早启动相比,tau正电子发射断层扫描摄取较高相关。
核心结论
- 本研究中,女性与年龄匹配男性相比tau较高,尤其在β淀粉样蛋白升高情况下;女性中较早绝经年龄和激素治疗晚启动与tau易感性增加相关,尤其当新皮质β淀粉样蛋白升高时。这些观察性发现提示部分女性亚群可能处于更高病理负荷风险。
研究设计与样本
- 横断面研究,纳入威斯康星阿尔茨海默病预防登记处认知正常且至少有一次18F-MK-6240和11C-匹兹堡化合物B正电子发射断层扫描的男性和女性,数据收集于2006年11月至2021年5月。
- 共292名认知正常个体,女性193名(66.1%),男性99名(33.9%);tau扫描平均(范围)年龄67(49-80)岁;52名(19%)β淀粉样蛋白异常;106名(36.3%)为APOEε4携带者。
- 暴露包括过早绝经(绝经年龄小于40岁)、早期绝经(绝经年龄40-45岁)和常规绝经(绝经年龄大于45岁),以及激素治疗使用者(当前/过去使用)和非使用者(当前/过去未使用),暴露为自我报告。
主要发现
- 在β淀粉样蛋白升高个体中,女性性别(标准化β = -0.41;95% CI,-0.97至-0.32;P < .001)、较早绝经年龄(标准化β = -0.38;95% CI,-0.14至-0.09;P < .001)和激素治疗使用(标准化β = 0.31;95% CI,0.40-1.20;P = .008)与较高区域tau正电子发射断层扫描摄取相关,分别 compared with 男性性别、较晚绝经年龄和激素治疗未使用。
- 受累区域包括颞叶和枕叶的内侧和外侧区域。
- 激素治疗晚启动(绝经后超过5年)与较早启动相比,tau正电子发射断层扫描摄取较高相关(β = 0.49;95% CI,0.27-0.43;P = .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Postmenopausal females represent around 70% of all individuals with Alzheimer disease. Previous literature shows elevated levels of tau in cognitively unimpaired postmenopausal females compared with age-matched males, particularly in the setting of high β-amyloid (Aβ). The biological mechanisms associated with higher tau deposition in female individuals remain elusive. OBJECTIVE: To examine the extent to which sex, age at menopause, and hormone therapy (HT) use are associated with regional tau at a given level of Aβ, both measured with positron emission tomography (PET). DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included participants enrolled in the Wisconsin Registry for Alzheimer Prevention. Cognitively unimpaired males and females with at least 1 18F-MK-6240 and 11C-Pittsburgh compound B PET scan were analyzed. Data were collected between November 2006 and May 2021. EXPOSURES: Premature menopause (menopause at younger than 40 years), early menopause (menopause at age 40-45 years), and regular menopause (menopause at older than 45 years) and HT user (current/past use) and HT nonuser (no current/past use). Exposures were self-reported. MAIN OUTCOMES AND MEASURES: Seven tau PET regions that show sex differences across temporal, parietal, and occipital lobes. Primary analyses examined the interaction of sex, age at menopause or HT, and Aβ PET on regional tau PET in a series of linear regressions. Secondary analyses investigated the influence of HT timing in association with age at menopause on regional tau PET. RESULTS: Of 292 cognitively unimpaired individuals, there were 193 females (66.1%) and 99 males (33.9%). The mean (range) age at tau scan was 67 (49-80) years, 52 (19%) had abnormal Aβ, and 106 (36.3%) were APOEε4 carriers. There were 98 female HT users (52.2%) (past/current). Female sex (standardized β = -0.41; 95% CI, -0.97 to -0.32; P < .001), earlier age at menopause (standardized β = -0.38; 95% CI, -0.14 to -0.09; P < .001), and HT use (standardized β = 0.31; 95% CI, 0.40-1.20; P = .008) were associated with higher regional tau PET in individuals with elevated Aβ compared with male sex, later age at menopause, and HT nonuse. Affected regions included medial and lateral regions of the temporal and occipital lobes. Late initiation of HT (>5 years following age at menopause) was associated with higher tau PET compared with early initiation (β = 0.49; 95% CI, 0.27-0.43; P = .001). CONCLUSIONS AND RELEVANCE: In this study, females exhibited higher tau compared with age-matched males, particularly in the setting of elevated Aβ. In females, earlier age at menopause and late initiation of HT were associated with increased tau vulnerability especially when neocortical Aβ elevated. These observational findings suggest that subgroups of female individuals may be at higher risk of pathological burden.
引用
- Coughlan GT, Betthauser TJ, Boyle R, et al. Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography. JAMA Neurol. 2023. PMID: 37010830. doi:10.1001/jamaneurol.2023.0455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。